Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin after partial parotidectomy for prevention of sialocele and salivary fistula
IRCT20210923052559N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of neuronox in parotid neoplasm (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Swelling of the fistula and sialocele. Started Feb 2023; status: completed.
02
Drugs
neuronox
03
Conditions
parotid neoplasm
Beyond the preview
Go deeper on IRCT20210923052559N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210923052559N2.